Literature DB >> 26541919

Importance of angina in patients with coronary disease, heart failure, and left ventricular systolic dysfunction: insights from STICH.

E Marc Jolicœur1, Allison Dunning2, Serenella Castelvecchio3, Rafal Dabrowski4, Myron A Waclawiw5, Mark C Petrie6, Ralph Stewart7, Pardeep S Jhund8, Patrice Desvigne-Nickens5, Julio A Panza9, Robert O Bonow10, Benjamin Sun11, Tan Ru San12, Hussein R Al-Khalidi2, Jean L Rouleau1, Eric J Velazquez2, John G F Cleland13.   

Abstract

BACKGROUND: Patients with left ventricular (LV) systolic dysfunction, coronary artery disease (CAD), and angina are often thought to have a worse prognosis and a greater prognostic benefit from coronary artery bypass graft (CABG) surgery than those without angina.
OBJECTIVES: This study investigated: 1) whether angina was associated with a worse prognosis; 2) whether angina identified patients who had a greater survival benefit from CABG; and 3) whether CABG improved angina in patients with LV systolic dysfunction and CAD.
METHODS: We performed an analysis of the STICH (Surgical Treatment for Ischemic Heart Failure) trial, in which 1,212 patients with an ejection fraction ≤35% and CAD were randomized to CABG or medical therapy. Multivariable Cox and logistic models were used to assess long-term clinical outcomes.
RESULTS: At baseline, 770 patients (64%) reported angina. Among patients assigned to medical therapy, all-cause mortality was similar in patients with and without angina (hazard ratio [HR]: 1.05; 95% confidence interval [CI]: 0.79 to 1.38). The effect of CABG was similar whether the patient had angina (HR: 0.89; 95% CI: 0.71 to 1.13) or not (HR: 0.68; 95% CI: 0.50 to 0.94; p interaction = 0.14). Patients assigned to CABG were more likely to report improvement in angina than those assigned to medical therapy alone (odds ratio: 0.70; 95% CI: 0.55 to 0.90; p < 0.01).
CONCLUSIONS: Angina does not predict all-cause mortality in medically treated patients with LV systolic dysfunction and CAD, nor does it identify patients who have a greater survival benefit from CABG. However, CABG does improve angina to a greater extent than medical therapy alone. (Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease [STICH]; NCT00023595).
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  coronary artery bypass grafting; coronary artery disease; heart failure; mortality

Mesh:

Year:  2015        PMID: 26541919      PMCID: PMC4655599          DOI: 10.1016/j.jacc.2015.08.882

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  24 in total

1.  Guidelines on myocardial revascularization.

Authors:  Philippe Kolh; William Wijns; Nicolas Danchin; Carlo Di Mario; Volkmar Falk; Thierry Folliguet; Scot Garg; Kurt Huber; Stefan James; Juhani Knuuti; Jose Lopez-Sendon; Jean Marco; Lorenzo Menicanti; Miodrag Ostojic; Massimo F Piepoli; Charles Pirlet; Jose L Pomar; Nicolaus Reifart; Flavio L Ribichini; Martin J Schalij; Paul Sergeant; Patrick W Serruys; Sigmund Silber; Miguel Sousa Uva; David Taggart
Journal:  Eur J Cardiothorac Surg       Date:  2010-09       Impact factor: 4.191

2.  Symptoms in patients with heart failure are prognostic predictors: insights from COMET.

Authors:  Inger Ekman; John G F Cleland; Karl Swedberg; Andrew Charlesworth; Marco Metra; Philip A Poole-Wilson
Journal:  J Card Fail       Date:  2005-05       Impact factor: 5.712

3.  The Heart Failure Revascularisation Trial (HEART).

Authors:  John G F Cleland; Melanie Calvert; Nick Freemantle; Yvonne Arrow; Stephen G Ball; Robert S Bonser; Sudipta Chattopadhyay; Michael S Norell; Dudley J Pennell; Roxy Senior
Journal:  Eur J Heart Fail       Date:  2010-12-13       Impact factor: 15.534

4.  Myocardial viability and survival in ischemic left ventricular dysfunction.

Authors:  Robert O Bonow; Gerald Maurer; Kerry L Lee; Thomas A Holly; Philip F Binkley; Patrice Desvigne-Nickens; Jaroslaw Drozdz; Pedro S Farsky; Arthur M Feldman; Torsten Doenst; Robert E Michler; Daniel S Berman; Jose C Nicolau; Patricia A Pellikka; Krzysztof Wrobel; Nasri Alotti; Federico M Asch; Liliana E Favaloro; Lilin She; Eric J Velazquez; Robert H Jones; Julio A Panza
Journal:  N Engl J Med       Date:  2011-04-04       Impact factor: 91.245

5.  F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2).

Authors:  Rob S B Beanlands; Graham Nichol; Ella Huszti; Dennis Humen; Normand Racine; Michael Freeman; Karen Y Gulenchyn; Linda Garrard; Robert deKemp; Ann Guo; Terrence D Ruddy; Francois Benard; André Lamy; Robert M Iwanochko
Journal:  J Am Coll Cardiol       Date:  2007-10-10       Impact factor: 24.094

6.  Atypical presentations among Medicare beneficiaries with unstable angina pectoris.

Authors:  John G Canto; Contessa Fincher; Catarina I Kiefe; Jeroan J Allison; Qing Li; Ellen Funkhouser; Robert M Centor; Harry P Selker; Norman W Weissman
Journal:  Am J Cardiol       Date:  2002-08-01       Impact factor: 2.778

7.  The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial.

Authors:  Eric J Velazquez; Kerry L Lee; Christopher M O'Connor; Jae K Oh; Robert O Bonow; Gerald M Pohost; Arthur M Feldman; Daniel B Mark; Julio A Panza; George Sopko; Jean L Rouleau; Robert H Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2007-12       Impact factor: 5.209

8.  Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.

Authors:  Patrick W Serruys; Marie-Claude Morice; A Pieter Kappetein; Antonio Colombo; David R Holmes; Michael J Mack; Elisabeth Ståhle; Ted E Feldman; Marcel van den Brand; Eric J Bass; Nic Van Dyck; Katrin Leadley; Keith D Dawkins; Friedrich W Mohr
Journal:  N Engl J Med       Date:  2009-02-18       Impact factor: 91.245

9.  Coronary bypass surgery with or without surgical ventricular reconstruction.

Authors:  Robert H Jones; Eric J Velazquez; Robert E Michler; George Sopko; Jae K Oh; Christopher M O'Connor; James A Hill; Lorenzo Menicanti; Zygmunt Sadowski; Patrice Desvigne-Nickens; Jean-Lucien Rouleau; Kerry L Lee
Journal:  N Engl J Med       Date:  2009-03-29       Impact factor: 91.245

10.  A randomized trial of therapies for type 2 diabetes and coronary artery disease.

Authors:  Robert L Frye; Phyllis August; Maria Mori Brooks; Regina M Hardison; Sheryl F Kelsey; Joan M MacGregor; Trevor J Orchard; Bernard R Chaitman; Saul M Genuth; Suzanne H Goldberg; Mark A Hlatky; Teresa L Z Jones; Mark E Molitch; Richard W Nesto; Edward Y Sako; Burton E Sobel
Journal:  N Engl J Med       Date:  2009-06-07       Impact factor: 91.245

View more
  10 in total

1.  Rethinking Revascularization in Left Ventricular Systolic Dysfunction.

Authors:  Adam D DeVore; Eric J Velazquez
Journal:  Circ Heart Fail       Date:  2017-01       Impact factor: 8.790

2.  Interventional therapies in ischemic ventricular dysfunction: facts and versions!

Authors:  Paulo Cury Rezende; Diogo Freitas Cardoso de Azevedo; Whady Hueb
Journal:  Ann Transl Med       Date:  2016-10

Review 3.  Cardiac surgery 2015 reviewed.

Authors:  Torsten Doenst; Constanze Strüning; Alexandros Moschovas; David Gonzalez-Lopez; Yasin Essa; Hristo Kirov; Mahmoud Diab; Gloria Faerber
Journal:  Clin Res Cardiol       Date:  2016-06-29       Impact factor: 5.460

Review 4.  Assessing Prognosis of Acute Coronary Syndrome in Recent Clinical Trials: A Systematic Review.

Authors:  Fan Ye; David Winchester; Michael Jansen; Arthur Lee; Burton Silverstein; Carolyn Stalvey; Matheen Khuddus; Joseph Mazza; Steven Yale
Journal:  Clin Med Res       Date:  2019-06

5.  Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial.

Authors:  Renato D Lopes; Karen P Alexander; Susanna R Stevens; Harmony R Reynolds; Gregg W Stone; Ileana L Piña; Frank W Rockhold; Ahmed Elghamaz; Jose Luis Lopez-Sendon; Pedro S Farsky; Alexander M Chernyavskiy; Ariel Diaz; Denis Phaneuf; Mark A De Belder; Yi-Tong Ma; Luis A Guzman; Michel Khouri; Alessandro Sionis; Derek J Hausenloy; Rolf Doerr; Joseph B Selvanayagam; Aldo Pietro Maggioni; Judith S Hochman; David J Maron
Journal:  Circulation       Date:  2020-08-29       Impact factor: 29.690

6.  Relation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION).

Authors:  Kishan S Parikh; Adrian Coles; Phillip J Schulte; William E Kraus; Jerome L Fleg; Steven J Keteyian; Ileana L Piña; Mona Fiuzat; David J Whellan; Christopher M O'Connor; Robert J Mentz
Journal:  Am J Cardiol       Date:  2016-07-29       Impact factor: 2.778

7.  Six-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathy.

Authors:  Ralph A H Stewart; Dominika Szalewska; Amanda Stebbins; Hussein R Al-Khalidi; John G H Cleland; Andrzej Rynkiewicz; Mark H Drazner; Harvey D White; Daniel B Mark; Ambuj Roy; Dragana Kosevic; Miroslaw Rajda; Marek Jasinski; Chua Yeow Leng; Wiwun Tungsubutra; Patrice Desvigne-Nickens; Eric J Velazquez; Mark C Petrie
Journal:  Open Heart       Date:  2018-02-20

Review 8.  Co-morbidities and co-medications as confounders of cardioprotection-Does it matter in the clinical setting?

Authors:  Petra Kleinbongard; Hans Erik Bøtker; Michel Ovize; Derek J Hausenloy; Gerd Heusch
Journal:  Br J Pharmacol       Date:  2020-01-03       Impact factor: 8.739

9.  Myocardial viability testing: all STICHed up, or about to be REVIVED?

Authors:  Matthew Ryan; Holly Morgan; Amedeo Chiribiri; Eike Nagel; John Cleland; Divaka Perera
Journal:  Eur Heart J       Date:  2022-01-13       Impact factor: 29.983

Review 10.  To Revascularise or Not To Revascularise, That Is the Question: the Diagnostic and Management Conundrum of Ischaemic Cardiomyopathy.

Authors:  Natalia Briceno; Divaka Perera
Journal:  Curr Cardiol Rep       Date:  2016-06       Impact factor: 2.931

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.